Intellia Therapeutics (NASDAQ:NTLA) just reported results for the second quarter of 2024.
- Intellia Therapeutics reported earnings per share of -$1.52. This was below the analyst estimate for EPS of -$1.23.
- The company reported revenue of $6.96 million.
- This was 63.69% worse than the analyst estimate for revenue of $19.16 million.